Cherkin A, Exkardt MJ. Effects of dimethylaminoethanol upon life-span and behavior of aged Japanese quail. J Gerontol 1977;32:38-45. View abstract.
Coleman N, Dexheimer P, DiMascio A, et al. Deanol in the treatment of hyperkinetic children. Psychosomatics 1976;17(2):68-72. View abstract.
Davies C, Maidment S, Hanley P, et al. Dimethylaminoethanol (DMAE). HSE. Risk assessment document; EH72/2;1997. (TOXLINE).
de Montigny C, Chouinard G, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berl) 1979;65:219-23. View abstract.
Ferris SH, Sathananthan G, Gershon S, et al. Senile dementia: treatment with deanol. J Am Geriatr Soc 1977;25:241-4. View abstract.
Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in Alzheimer's disease. Am J Psychiatry 1981;138:970-2. View abstract.
George J, Pridmore S, Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry 1981;15:68-71. View abstract.
Haug BA, Holzgraefe M. Orofacial and respiratory tardive dyskinesia: potential side effects of 2-dimethylaminoethanol (deanol)? Eur Neurol 1991;31:423-5. View abstract.
Jus A, Villeneuve A, Gautier J, et al. Deanol, lithium and placebo in the treatment of tardive dyskinesia. A double-blind crossover study. Neuropsychobiology 1978;4:140-9. View abstract.
Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Clin Pharmacol Ther 1975;17:534-40. View abstract.
Lindeboom SF, Lakke JP. Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias. Acta Neurol Scand 1978;58:134-8. View abstract.
McGrath JJ, Soares KVS. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2000;(2):CD000207. View abstract.
Oettinger L Jr. Pediatric psychopharmacology. A review with special reference to deanol. Dis Nerv Syst 1977;38:25-31.
Osol A, Hoover JE, eds. Remington's Pharmaceutical Science, 15th ed. Easton, PA: Mack Publishing Company, 1975.
Penovich P, Morgan JP, Kerzner B, et al. Double-blind evaluation of deanol in tardive dyskinesia. JAMA 1978;239:1997-8. View abstract.
Pfeiffer CC, Jenny EH, Gallagher W, et al. Stimulant effect of 2-dimethylaminoethanol; possible precursor of brain acetylcholine. Science 1957;126(3274):610-1. View abstract.
Pieralisi G, Ripari P, Vecchiet L. Effects of a standardized ginseng extract combined with dimethylaminoethanol bitartrate, vitamins, minerals, and trace elements on physical performance during exercise. Clin Ther 1991;13:373-82. View abstract.
Re O. 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Ther Res Clin Exp 1974;16:1238-42.
Sergio W. Use of DMAE (2-dimethylaminoethanol) in the induction of lucid dreams. Med Hypotheses 1988;26:255-7. View abstract.
Soares KV, McGrath JJ. The treatment of tardive dyskinesia- a systematic review and meta-analysis. Schizophr Res 1999;39:1-16; discussion 17-18. View abstract.
Stenback F, Weisburger JH, Williams GM. Effect of lifetime administration of dimethylaminoethanol on longevity, aging changes, and cryptogenic neoplasms in C3H mice. Mech Ageing Dev 1988;42:129-38. View abstract.
Uhoda I, Faska N, Robert C, et al. Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. Skin Res Technol 2002;8:164-7. View abstract.
Casey DE. Mood alterations during deanol therapy. Psychopharmacology (Berl) 1979;62:187-91. View abstract.